MATINAS BIOPHARMA HOLDINGS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.166 USD | +0.61% |
|
-2.35% | -23.22% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 41.38M |
|---|---|---|---|---|---|
| Net income 2024 * | -25M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-1.5
x | Employees | 32 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Matinas BioPharma Holdings, Inc.
More press releases
| 1 day | +0.61% | ||
| 1 week | -2.35% | ||
| Current month | -10.61% | ||
| 1 month | -8.69% | ||
| 3 months | -38.29% | ||
| 6 months | -20.95% | ||
| Current year | -23.22% |
1 week
0.16
0.17
1 month
0.160.19
Current year
0.160.43
1 year
0.110.89
3 years
0.111.61
5 years
0.112.49
10 years
0.113.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 13-04-30 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 19-01-02 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 20-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 13-04-30 |
Natasha Giordano
BRD | Director/Board Member | 62 | 20-09-13 |
Eric Ende
CHM | Chairman | 55 | 17-04-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.166 | +0.61% | 330 857 |
| 24-05-23 | 0.165 | -1.61% | 499,456 |
| 24-05-22 | 0.1677 | +1.64% | 754,146 |
| 24-05-21 | 0.165 | -1.49% | 916,661 |
| 24-05-20 | 0.1675 | -1.47% | 1,390,869 |
Delayed Quote Nyse, May 24, 2024 at 02:15 pm EDT
More quotes
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.165
USD
Average target price
0.8667
USD
Spread / Average Target
+425.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.22% | 41.38M | |
| +12.23% | 116B | |
| +12.76% | 106B | |
| -9.35% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.45% | 16.33B | |
| +6.24% | 14.14B | |
| +29.86% | 12.02B |
- Stock Market
- Equities
- MTNB Stock
